Compare Ally Financial Inc (ALLY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Sana Biotechnology Inc — how do they compare? Ally Financial Inc trades at $43.92 (market cap $13.37B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Ally Financial Inc is far larger — about 11.8× Sana Biotechnology Inc's market cap, and Ally Financial Inc pays a 2.73% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ALLY | SANA | |
|---|---|---|
Market Cap | $13.37B | $1.13B |
Sector | Financials | Health |
52-Week High | $47.25 | $5.92 |
52-Week Low | $35.96 | $2.68 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $44.14, up 0.8% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed earnings, beating estimates in Q1 2026 but missing in Q2, while maintaining a P/E of 10.34 and P/B of 0.99, indicating potential undervaluation. Recent news includes insider sales and corporate recognitions, alongside a declared $0.30 dividend payable in August 2026.
The outlook for ALLY is cautiously optimistic, with a consensus price target of $54.40 offering ~23% upside, though risks from higher provisions and macroeconomic pressures persist. Investment appeal lies in its low valuation and dividend, but investors must weigh credit risks and interest rate sensitivity against growth in auto finance and digital banking strengths.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
